The battle of biologics modalities
23 Sep 2024
Emerging Technologies
){kind=logo}
- Single Domain Antibodies vs scFvs – advantages and limitations (discovery platforms, reformatting, physicochemical properties)
- Common Light Chain Discovery - key risk factors for a successful campaign
- T-cell Engagers vs CARs, ADCs vs radiolabeled antibodies – who will win the battle?
